Advanced Biomed Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Net Income	-3.37	-2.78	-3.73	-4.03	-1.84
Depreciation & Amortization	0.3	0.27	0.23	0.11	0.06
Other Amortization	0.13	0.13	0.14	0.01	-
Loss (Gain) From Sale of Assets	-	-	0.15	0.04	-
Asset Writedown & Restructuring Costs	-	-	-	1.62	-
Change in Accounts Payable	0.28	0.48	0.38	0.91	0.02
Change in Other Net Operating Assets	-2.11	-0.22	-0.13	0.59	1.29
Operating Cash Flow	-4.76	-2.13	-2.96	-0.74	-0.47
Capital Expenditures	-0.06	-0.07	-0.21	-0.89	-0.03
Sale of Property, Plant & Equipment	-	-	-	0.03	-
Cash Acquisitions	-	-	-	0.2	-
Divestitures	-	-	-0.05	-	-
Sale (Purchase) of Intangibles	-	-	-0	-0.42	-
Investing Cash Flow	-0.06	-0.07	-0.26	-1.08	-0.03
Long-Term Debt Issued	-	1.66	-	-	-
Net Debt Issued (Repaid)	1.21	1.66	-	-	-
Issuance of Common Stock	-	-	1.01	6.1	0.7
Other Financing Activities	5.81	0.21	-0.55	-	-
Financing Cash Flow	7.02	1.87	0.46	6.1	0.7
Foreign Exchange Rate Adjustments	0.32	0.32	0.61	0.45	-0.2
Net Cash Flow	2.52	-0.01	-2.16	4.72	0
Free Cash Flow	-4.82	-2.2	-3.17	-1.63	-0.5
Free Cash Flow Per Share	-0.24	-0.11	-0.16	-0.12	-0.04
Levered Free Cash Flow	-	-1.93	-1.4	0.69	-
Unlevered Free Cash Flow	-	-1.93	-1.4	0.69	-
Change in Net Working Capital	-	0.67	-0.36	-3.36	-

Updated Jan 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q